Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to City of Hope, Alnylam, and More

Premium

Title: RNA Sequence-specific Mediators of RNA Interference

Patent Number: 8,790,922

Filed: Oct. 4, 2010

Lead Inventor: Thomas Tuschl, Max Planck Institute


Title: Double-stranded and Single-stranded RNA Molecules with 5' Triphosphates and Their Use for Inducing Interferon

Patent Number: 8,791,082

Filed: Sept. 21, 2007

Lead Inventor: John Rossi, City of Hope


Title: Nuclear Reprogramming Factor Comprising miRNA and a Protein Factor

Patent Number: 8,791,248

Filed: Dec. 7, 2011

Lead Inventor: Shinya Yamanaka, Kyoto University


Title: Compositions and Methods for Inhibiting Expression of the HAMP Gene

Patent Number: 8,791,250

Filed: May 23, 2013

Lead Inventor: Tomoko Nakayama, Alnylam Pharmaceuticals

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.